BDBM251918 US10065961, Compound 17::US10683295, Compound 17::US10941151, Compound 17::US9475814, 17

SMILES C[C@H]1N(CCn2c1nnc2-c1csc(n1)N(C)C)C(=O)c1ccc(cc1)-c1cccs1

InChI Key InChIKey=FFFWLCPVZQDKGV-CQSZACIVSA-N

Data  15 KI  2 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 17 hits for monomerid = 251918   

TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251918(US10065961, Compound 17 | US10683295, Compound 17 ...)
Affinity DataKi:  7nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251918(US10065961, Compound 17 | US10683295, Compound 17 ...)
Affinity DataKi:  7nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251918(US10065961, Compound 17 | US10683295, Compound 17 ...)
Affinity DataKi:  7nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251918(US10065961, Compound 17 | US10683295, Compound 17 ...)
Affinity DataKi:  7nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251918(US10065961, Compound 17 | US10683295, Compound 17 ...)
Affinity DataKi:  7nMAssay Description:The antagonist activity of compounds of the invention is measured following pre-incubation (3 minutes) of the compound with the cells, followed by ad...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251918(US10065961, Compound 17 | US10683295, Compound 17 ...)
Affinity DataKi:  7nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251918(US10065961, Compound 17 | US10683295, Compound 17 ...)
Affinity DataKi:  7nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSubstance-P receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251918(US10065961, Compound 17 | US10683295, Compound 17 ...)
Affinity DataKi:  6.06E+3nMAssay Description:NK1: The affinity of compounds of the invention for the NK1 receptor was evaluated in CHO recombinant cells which express the human NK1 receptor. Mem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSubstance-P receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251918(US10065961, Compound 17 | US10683295, Compound 17 ...)
Affinity DataKi:  6.06E+3nMAssay Description:NK1: The following radioligand: [3H] substance P (PerkinElmer Cat#NET111520) was used in this assay. Binding assays were performed in a 50 mM Tris/5 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSubstance-P receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251918(US10065961, Compound 17 | US10683295, Compound 17 ...)
Affinity DataKi:  6.06E+3nM ΔG°:  -7.11kcal/molepH: 7.4 T: 2°CAssay Description:The affinity of compounds of the invention for the NK1 receptor was evaluated in CHO recombinant cells which express the human NK1 receptor. Membrane...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSubstance-P receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251918(US10065961, Compound 17 | US10683295, Compound 17 ...)
Affinity DataKi:  6.06E+3nM ΔG°:  -7.11kcal/molepH: 7.4 T: 2°CAssay Description:The affinity of compounds of the invention for the NK1 receptor was evaluated in CHO recombinant cells which express the human NK1 receptor. Membrane...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSubstance-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251918(US10065961, Compound 17 | US10683295, Compound 17 ...)
Affinity DataKi:  9.95E+3nMAssay Description:NK2: Binding assays were performed in a 25 mM HEPES/1 mM CaCl2/5 mM MgCl2/0.5% BSA/10 μg/ml saponin, at pH 7.4. Binding assays consisted of 25 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSubstance-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251918(US10065961, Compound 17 | US10683295, Compound 17 ...)
Affinity DataKi:  9.95E+3nM ΔG°:  -6.82kcal/molepH: 7.4 T: 2°CAssay Description:The affinity of compounds of the invention for the NK2 receptor was evaluated in CHO recombinant cells which express the human NK2 receptor. Membrane...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSubstance-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251918(US10065961, Compound 17 | US10683295, Compound 17 ...)
Affinity DataKi:  9.95E+3nM ΔG°:  -6.82kcal/molepH: 7.4 T: 2°CAssay Description:The affinity of compounds of the invention for the NK2 receptor was evaluated in CHO recombinant cells which express the human NK2 receptor. Membrane...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSubstance-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251918(US10065961, Compound 17 | US10683295, Compound 17 ...)
Affinity DataKi:  9.95E+3nMAssay Description:NK2: The affinity of compounds of the invention for the NK2 receptor was evaluated in CHO recombinant cells which express the human NK2 receptor. Mem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251918(US10065961, Compound 17 | US10683295, Compound 17 ...)
Affinity DataIC50:  7nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251918(US10065961, Compound 17 | US10683295, Compound 17 ...)
Affinity DataIC50:  7nMAssay Description:The antagonist activity of compounds of the invention is measured following pre-incubation (3 minutes) of the compound with the cells, followed by ad...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent